Galera Therapeutics, Inc. (NasdaqGM:GRTX) has engaged Stifel, Nicolaus & Company, Inc. to assist in reviewing strategic alternatives for the Company and its portfolio of dismutase mimetics with the goal of maximizing value for its shareholders. Such alternatives may include a merger, sale, divestiture of assets, licensing, or other strategic transaction. If the Company is unable to undertake any strategic alternative, it may be required to cease operations altogether.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.176 USD | -0.62% | -5.38% | +21.05% |
04-03 | North American Morning Briefing : Powell Awaited -2- | DJ |
03-28 | Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+21.05% | 9.63M | |
+2.82% | 108B | |
+10.25% | 104B | |
+2.27% | 22.33B | |
-11.76% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-8.53% | 17.64B | |
+6.25% | 14.05B | |
+35.26% | 12.51B |
- Stock Market
- Equities
- GRTX Stock
- News Galera Therapeutics, Inc.
- Galera Therapeutics Announces Review of Strategic Alternatives